Gyoung Tae Noh

Prof. Dr. Gyoung Tae Noh


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in The International Journal of Medical Robotics and Computer Assisted Surgery
Verified
Journal Article
Closed access
PDF file
GNGyoung Tae Noh
Gyoung Tae Noh
BOBo‐Young Oh
Bo‐Young Oh
MHMyunghyun Han
Myunghyun Han
SCSoon Sup Chung
Soon Sup Chung
RLRyung‐Ah Lee
Ryung‐Ah Lee
KKKwang Ho Kim
Kwang Ho Kim

27 March 2023 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
HKH. S. Kim
H. S. Kim
BOB.-Y. Oh
B.-Y. Oh
CCC. Cheong
C. Cheong
MPM. H. Park
M. H. Park
SCS. S. Chung
S. S. Chung
GNGyoung Tae Noh
Gyoung Tae Noh

30 April 2024 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
HRHyo Seon Ryu
Hyo Seon Ryu
HKHyun Jung Kim
Hyun Jung Kim
WJWoong Bae Ji
Woong Bae Ji
BKByung Chang Kim
Byung Chang Kim
JKJi Hun Kim
Ji Hun Kim
KCKorean Colon Cancer Multidisciplinary Committee
Korean Colon Cancer Multidisciplinary Committee
Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee.

4 July 2023 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
HKHo Seung Kim
Ho Seung Kim
BOBo-Young Oh
Bo-Young Oh
SCSoon Sup Chung
Soon Sup Chung
RLRyung-Ah Lee
Ryung-Ah Lee
GNGyoung Tae Noh
Gyoung Tae Noh

Verified
Journal Article
Open access
PDF file
MKMinsung Kim
Minsung Kim
ISIl Tae Son
Il Tae Son
GNGyoung Tae Noh
Gyoung Tae Noh
SWSo-Youn Woo
So-Youn Woo
RLRyung-Ah Lee
Ryung-Ah Lee
BOBo Young Oh
Bo Young Oh
Cancer-cell-derived exosomes confer oncogenic properties in their tumor microenvironment and to other cells; however, the exact mechanism underlying this process is unclear. Here, we investigated the roles of cancer-cell-derived exosomes in colon cancer. Exosomes were isolated from colon cancer cell lines, HT-29, SW480, and LoVo, using an ExoQuick-TC kit, identified using Western blotting for exosome markers, and characterized using transmission electron microscopy and nanosight tracking analysis. The isolated exosomes were used to treat HT-29 to evaluate their effect on cancer progression, specifically cell viability and migration. Cancer-associated fibroblasts (CAFs) were obtained from patients with colorectal cancer to analyze the effect of the exosomes on the tumor microenvironment. RNA sequencing was performed to evaluate the effect of the exosomes on the mRNA component of CAFs. The results showed that exosome treatment significantly increased cancer cell proliferation, upregulated N-cadherin, and downregulated E-cadherin. Exosome-treated cells exhibited higher motility than control cells. Compared with control CAFs, exosome-treated CAFs showed more downregulated genes. The exosomes also altered the regulation of different genes involved in CAFs. In conclusion, colon cancer-cell-derived exosomes affect cancer cell proliferation and the epithelial–mesenchymal transition. They promote tumor progression and metastasis and affect the tumor microenvironment.

31 December 2024 in Annals of Coloproctology
Verified
Journal Article
Open access
EPEun Ji Park
Eun Ji Park
GNGyoung Tae Noh
Gyoung Tae Noh
YLYong Joon Lee
Yong Joon Lee
MPMin Young Park
Min Young Park
YHYoon Dae Han
Yoon Dae Han
BMByung Soh Min
Byung Soh Min
Purpose: Robot-assisted surgery is readily applied to every type of colorectal surgeries. However, studies showing the safety and feasibility of robotic surgery (RS) have dealt with rectal cancer more than colon cancer. This study aimed to investigate how technical advantages of RS can translate into actual clinical outcomes that represent postoperative systemic response.Methods: This study retrospectively reviewed consecutive cases in a single tertiary medical center in Korea. Patients with primary colon cancer who underwent curative resection between 2006 and 2012 were included. Propensity score matching was done to adjust baseline patient characteristics (age, sex, body mass index, American Society of Anesthesiologists physical status, tumor profile, pathologic stage, operating surgeon, surgery extent) between open surgery (OS), laparoscopic surgery (LS), and RS groups.Results: After propensity score matching, there were 66 patients in each group for analysis, and there was no significant differences in baseline patient characteristics. Maximal postoperative leukocyte count was lowest in the RS group and highest in the OS group (P=0.021). Similar results were observed for postoperative neutrophil count (P=0.024). Postoperative prognostic nutritional index was highest in the RS group and lowest in the OS group (P<0.001). The time taken to first flatus and soft diet resumption was longest in the OS group and shortest in the RS group (P=0.001 and P<0.001, respectively). Among all groups, other short-term postoperative outcomes such as hospital stay and complications did not show significant difference, and oncological survival results were similar.Conclusion: Better postoperative inflammatory indices in the RS group may correlate with their faster recovery of bowel motility and diet resumption compared to LS and OS groups.